Regenerative Medicine Foundation
  • Leadership
  • What We Do
    • Policy
    • Advocacy
    • Education & Outreach
  • Events
    • Regenerative Medicine Essentials
    • World Stem Cell Summit
    • Exploring Public Policy: Regenerative Medicine and Cell Therapies
    • Congressional Briefings
    • Regenerative Medicine and Stem Cell Action Awards
    • World Stem Cell Summit – CHINA
  • Membership/Register
    • Membership – Register for WSCS and RME Course
    • Donate
    • Amazon SMILE
  • News
    • News
    • Portraits of Hope
    • Video
    • Video Chats
  • Contact
Select Page

Longeveron Aging Frailty Phase 2b Trial

by Kevin McMahon | Jan 21, 2018 | News & Opinions, Science

Longeveron is currently enrolling subjects in its Phase 2b multi-center clinical trial designed to test the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) for the treatment of subjects with clinically diagnosed with Aging Frailty. This is the only...

Aging Frailty with Influenza Vaccine Trial announced by Longeveron

by Kevin McMahon | Jan 21, 2018 | News & Opinions, Science

America is facing one of the worst influenza seasons in recent history. The influenza virus is one of the top ten causes of death in elderly people. Longeveron is conducting a multi-center, randomized, placebo controlled trial using its Longeveron Mesenchymal Stem...

Recent Posts

  • Human mesenchymal stem cells show promise in treating chronic lung infections
  • Longeveron Selected to Present at the 2021 World Stem Cell Summit Dr. Joshua Hare, Longeveron’s Chief Science Officer, to present during this year’s Longevity Session
  • Breakthrough Paper Outlines Path to Heart Regeneration After Cardiac Injury
  • Advancing the Development of Safe and Effective Regenerative Medicine Products
  • Clinical trial assesses stem cells’ ability to prevent major cause of preemie deaths
Tweets about @WSCSummit
CC Regenerative Medicine Foundation